{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:25:42Z","timestamp":1790299542548,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00210-023-02842-6","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:03:18Z","timestamp":1700578998000},"page":"2777-2791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of a methylxanthine vasodilator: pentoxifylline on the treatment of diabetic nephropathy\u2014a meta-analysis"],"prefix":"10.1007","volume":"397","author":[{"given":"Mingyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"2842_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11596-015-1437-y","volume":"3","author":"Z An","year":"2015","unstructured":"An Z, Dong X, Guo Y et al (2015) Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy. J Huazhong Univ Sci Technolog Med Sci 3:356\u2013361. https:\/\/doi.org\/10.1007\/s11596-015-1437-y","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"2842_CR2","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s13300-021-01168-x","volume":"12","author":"D Bell","year":"2021","unstructured":"Bell D (2021) Are the protean effects of pentoxifylline in the therapy of diabetes and its complications still relevant? Diabetes Ther 12:3025\u20133035. https:\/\/doi.org\/10.1007\/s13300-021-01168-x","journal-title":"Diabetes Ther"},{"key":"2842_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.pop.2020.08.004","volume":"4","author":"R Bonner","year":"2020","unstructured":"Bonner R, Albajrami O, Hudspeth J et al (2020) Diabetic kidney disease. Prim Care 4:645\u2013659. https:\/\/doi.org\/10.1016\/j.pop.2020.08.004","journal-title":"Prim Care"},{"key":"2842_CR4","doi-asserted-by":"publisher","unstructured":"Dal Canto E, Ceriello A, Ryden L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur. J Prev Cardiol (2_suppl):25\u201332. https:\/\/doi.org\/10.1177\/2047487319878371","DOI":"10.1177\/2047487319878371"},{"key":"2842_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40620-019-00607-0","volume":"4","author":"AM de Morales","year":"2019","unstructured":"de Morales AM, Goicoechea M, Verde E et al (2019) Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. J Nephrol 4:581\u2013587. https:\/\/doi.org\/10.1007\/s40620-019-00607-0","journal-title":"J Nephrol"},{"key":"2842_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000079121","volume":"3","author":"K DiPetrillo","year":"2004","unstructured":"DiPetrillo K, Gesek FA (2004) Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 3:352\u2013359. https:\/\/doi.org\/10.1159\/000079121","journal-title":"Am J Nephrol"},{"key":"2842_CR7","doi-asserted-by":"publisher","unstructured":"Donate-Correa J, Ferri CM, Sanchez-Quintana F et al (2020a) Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications. Front Med (Lausanne): 628289. https:\/\/doi.org\/10.3389\/fmed.2020.628289","DOI":"10.3389\/fmed.2020.628289"},{"key":"2842_CR8","doi-asserted-by":"publisher","unstructured":"Donate-Correa J, Luis-Rodriguez D, Martin-Nunez E et al (2020b) Inflammatory targets in diabetic nephropathy. J Clin Med 2. https:\/\/doi.org\/10.3390\/jcm9020458","DOI":"10.3390\/jcm9020458"},{"key":"2842_CR9","doi-asserted-by":"publisher","unstructured":"Donate-Correa J, Tagua VG, Ferri C et al (2019) Pentoxifylline for renal protection in diabetic kidney disease. A Model of Old Drugs for New Horizons. J Clin Med 3. https:\/\/doi.org\/10.3390\/jcm8030287","DOI":"10.3390\/jcm8030287"},{"key":"2842_CR10","first-page":"61","volume":"05","author":"Z Feng","year":"2017","unstructured":"Feng Z, Zhen J (2017) Analysis of effect of valsartan combined with pentoxifylline on diabetic nephropathy. J Anhui Med College 05:61\u201362","journal-title":"J Anhui Med College"},{"key":"2842_CR11","first-page":"26","volume":"1","author":"E Ferrari","year":"1987","unstructured":"Ferrari E, Fioravanti M, Patti AL et al (1987) Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients. Pharmatherapeutica 1:26\u201339","journal-title":"Pharmatherapeutica"},{"key":"2842_CR12","unstructured":"Gan N, Kong Y, Liu S (2003) Clinical observation of pentoxifylline in reducing proteinuria in patients with diabetic nephropathy. J Pract Med 12"},{"key":"2842_CR13","doi-asserted-by":"publisher","unstructured":"Garcia FA, Reboucas JF, Balbino TQ et al (2015) Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase. J Inflamm (Lond) 33. https:\/\/doi.org\/10.1186\/s12950-015-0080-5","DOI":"10.1186\/s12950-015-0080-5"},{"key":"2842_CR14","first-page":"49","volume":"1","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N et al (2016) Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol 1:49\u201356","journal-title":"J Nephropharmacol"},{"key":"2842_CR15","doi-asserted-by":"publisher","unstructured":"Ghorbani A, Omidvar B, Beladi-Mousavi S et al (2012) The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 6. https:\/\/doi.org\/10.3265\/Nefrologia.pre2012.Jun.11242","DOI":"10.3265\/Nefrologia.pre2012.Jun.11242"},{"key":"2842_CR16","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1007\/s00125-015-3687-4","volume":"1","author":"S Han","year":"2015","unstructured":"Han S, Kim H, Kim D et al (2015) Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes. Diabetologia 1:S343\u2013S344. https:\/\/doi.org\/10.1007\/s00125-015-3687-4","journal-title":"Diabetologia"},{"key":"2842_CR17","doi-asserted-by":"publisher","unstructured":"Inacio MD, Costa MC, Lima T et al (2020) Pentoxifylline mitigates renal glycoxidative stress in obese mice by inhibiting AGE\/RAGE signaling and increasing glyoxalase levels. Life Sci 118196. https:\/\/doi.org\/10.1016\/j.lfs.2020.118196","DOI":"10.1016\/j.lfs.2020.118196"},{"key":"2842_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/0300060516663094","volume":"2","author":"D Liu","year":"2017","unstructured":"Liu D, Wang LN, Li HX et al (2017) Pentoxifylline plus ACEIs\/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis. J Int Med Res 2:383\u2013398. https:\/\/doi.org\/10.1177\/0300060516663094","journal-title":"J Int Med Res"},{"key":"2842_CR19","doi-asserted-by":"publisher","unstructured":"Lv J, Lv L, and Zhao Y et al (2012) VaIsartan combined with pentoxifylline in the treatment of diabetic retinopathy and diabetic nephropathy. Rec Adv Ophthalmol 10:945\u2013948. https:\/\/doi.org\/10.13389\/j.cnki.rao.2012.10.005","DOI":"10.13389\/j.cnki.rao.2012.10.005"},{"key":"2842_CR20","doi-asserted-by":"publisher","unstructured":"Maruno S, Tanaka T, Nangaku M (2022) Exploring molecular targets in diabetic kidney disease. Kidney Res Clin Pract. https:\/\/doi.org\/10.23876\/j.krcp.21.251","DOI":"10.23876\/j.krcp.21.251"},{"key":"2842_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2008.01.025","volume":"3","author":"BB McCormick","year":"2008","unstructured":"McCormick BB, Sydor A, Akbari A et al (2008) The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 3:454\u2013463. https:\/\/doi.org\/10.1053\/j.ajkd.2008.01.025","journal-title":"Am J Kidney Dis"},{"key":"2842_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/13813455.2017.1419267","volume":"5","author":"OM Mehanna","year":"2018","unstructured":"Mehanna OM, El AA, Al-Shehri S et al (2018) Effect of phosphodiesterase inhibitors on renal functions and oxidant\/antioxidant parameters in streptozocin-induced diabetic rats. Arch Physiol Biochem 5:424\u2013429. https:\/\/doi.org\/10.1080\/13813455.2017.1419267","journal-title":"Arch Physiol Biochem"},{"key":"2842_CR23","first-page":"762","volume":"08","author":"Y Xue","year":"2021","unstructured":"Microvascular Complications Group Of Chinese Diabetes Society, Xue Y, Zhu D (2021) Clinical guideline for the prevention and treatment of diabetic kidney disease in China (2021 edition). Chin J Diabetes Mellitus 08:762\u2013784","journal-title":"Chin J Diabetes Mellitus"},{"key":"2842_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s13300-022-01250-y","volume":"5","author":"F Moosaie","year":"2022","unstructured":"Moosaie F, Rabizadeh S, Fallahzadeh A et al (2022) Effects of pentoxifylline on serum markers of diabetic nephropathy in type 2 diabetes. Diabetes Therapy 5:1023\u20131036. https:\/\/doi.org\/10.1007\/s13300-022-01250-y","journal-title":"Diabetes Therapy"},{"key":"2842_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10787-022-00993-1","volume":"3","author":"G Mostafa-Hedeab","year":"2022","unstructured":"Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI et al (2022) A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology 3:799\u2013809. https:\/\/doi.org\/10.1007\/s10787-022-00993-1","journal-title":"Inflammopharmacology"},{"key":"2842_CR26","doi-asserted-by":"publisher","unstructured":"Navarro J, Mora C, Muros M et al (2003) Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Ame J kidney Dis 2. https:\/\/doi.org\/10.1016\/s0272-6386(03)00651-6","DOI":"10.1016\/s0272-6386(03)00651-6"},{"key":"2842_CR27","doi-asserted-by":"publisher","unstructured":"Navarro J, Mora C, Muros M et al (2005) Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Ame Soc Nephrol: JASN 7. https:\/\/doi.org\/10.1681\/ASN.2005010001","DOI":"10.1681\/ASN.2005010001"},{"key":"2842_CR28","doi-asserted-by":"publisher","unstructured":"Navarro J, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Ame J Kidney Dis 3. https:\/\/doi.org\/10.1016\/s0272-6386(99)70182-4","DOI":"10.1016\/s0272-6386(99)70182-4"},{"key":"2842_CR29","doi-asserted-by":"publisher","unstructured":"Navarro-Gonz\u00e1lez J, Mora-Fern\u00e1ndez C, de Fuentes MM et al (2015) Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Ame Soc Nephrol: JASN 1. https:\/\/doi.org\/10.1681\/ASN.2014010012","DOI":"10.1681\/ASN.2014010012"},{"key":"2842_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0091270011433435","volume":"1","author":"A Nisi","year":"2013","unstructured":"Nisi A, Panfili M, De Rosa G et al (2013) Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation. J Clin Pharmacol 1:51\u201357. https:\/\/doi.org\/10.1177\/0091270011433435","journal-title":"J Clin Pharmacol"},{"key":"2842_CR31","first-page":"309","volume":"4","author":"F Oliaei","year":"2011","unstructured":"Oliaei F, Hushmand S, Khafri S et al (2011) Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Caspian J Inter Med 4:309\u2013313","journal-title":"Caspian J Inter Med"},{"key":"2842_CR32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1177\/106002809603000702","volume":"7-8","author":"CM Paap","year":"1996","unstructured":"Paap CM, Simpson KS, Horton MW et al (1996) Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother 7-8:724\u2013729. https:\/\/doi.org\/10.1177\/106002809603000702","journal-title":"Ann Pharmacother"},{"key":"2842_CR33","unstructured":"Pang J, Zhang X, Zhi Z (2003) Effect of pentoxifylline in the treatment of early diabetic nephropathy. Clin focus 20"},{"key":"2842_CR34","doi-asserted-by":"publisher","unstructured":"Rabizadeh S, Dehghani Firouzabadi F, Noshad S et al (2018) Beneficial effects of pentoxifylline plus losartan dual therapy in type 2 diabetes with nephropathy. Ame J Med Sci 5. https:\/\/doi.org\/10.1016\/j.amjms.2017.12.015","DOI":"10.1016\/j.amjms.2017.12.015"},{"key":"2842_CR35","doi-asserted-by":"publisher","unstructured":"Rodriguez-Mor\u00e1n M, Gonz\u00e1lez-Gonz\u00e1lez G, Berm\u00fadez-Barba M et al (2006) Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol 1. https:\/\/doi.org\/10.5414\/cnp66003","DOI":"10.5414\/cnp66003"},{"key":"2842_CR36","doi-asserted-by":"publisher","unstructured":"Roozbeh J, Banihashemi M, Ghezlou M et al (2010) Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Renal Failure 2. https:\/\/doi.org\/10.3109\/08860221003602645","DOI":"10.3109\/08860221003602645"},{"key":"2842_CR37","doi-asserted-by":"publisher","unstructured":"Sagoo MK, Gnudi L (2020) Diabetic nephropathy: an overview. Methods Mol Biol 3-7. https:\/\/doi.org\/10.1007\/978-1-4939-9841-8_1","DOI":"10.1007\/978-1-4939-9841-8_1"},{"key":"2842_CR38","doi-asserted-by":"publisher","unstructured":"Samsu N (2021) Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int 1497449. https:\/\/doi.org\/10.1155\/2021\/1497449","DOI":"10.1155\/2021\/1497449"},{"key":"2842_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41440-020-0412-6","volume":"7","author":"A Setiadi","year":"2020","unstructured":"Setiadi A, Korim WS, May CN et al (2020) Systemic administration of pentoxifylline attenuates the development of hypertension in renovascular hypertensive rats. Hypertens Res 7:667\u2013678. https:\/\/doi.org\/10.1038\/s41440-020-0412-6","journal-title":"Hypertens Res"},{"key":"2842_CR40","doi-asserted-by":"publisher","first-page":"CD006800","DOI":"10.1002\/14651858.CD006800.pub2","volume":"2","author":"D Shan","year":"2012","unstructured":"Shan D, Wu H, Yuan Q et al (2012) Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 2:CD006800. https:\/\/doi.org\/10.1002\/14651858.CD006800.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2842_CR41","unstructured":"Sui C, Sheng H, Yang Y (1999) Effect of pentoxifylline on diabetic nephropathy. Shanghai journal of preventive medicine 10"},{"key":"2842_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00210-017-1406-z","volume":"10","author":"A \u015awierczek","year":"2017","unstructured":"\u015awierczek A, Wyska E, Ba\u015b S et al (2017) PK\/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response. Naunyn Schmiedebergs Arch Pharmacol 10:1047\u20131059. https:\/\/doi.org\/10.1007\/s00210-017-1406-z","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2842_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11892-019-1133-6","volume":"4","author":"B Thomas","year":"2019","unstructured":"Thomas B (2019) The global burden of diabetic kidney disease: time trends and gender gaps. Curr Diab Rep 4:18. https:\/\/doi.org\/10.1007\/s11892-019-1133-6","journal-title":"Curr Diab Rep"},{"key":"2842_CR44","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11255-015-0968-2","volume":"5","author":"ML Tian","year":"2015","unstructured":"Tian ML, Shen Y, Sun ZL et al (2015) Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. Int Urol Nephrol 5:815\u2013822. https:\/\/doi.org\/10.1007\/s11255-015-0968-2","journal-title":"Int Urol Nephrol"},{"key":"2842_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"4","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG et al (2003) L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 4:229\u2013244. https:\/\/doi.org\/10.1016\/j.niox.2003.12.002","journal-title":"Nitric Oxide"},{"key":"2842_CR46","unstructured":"Zang Q, Su R (1999) The effect of pentoxifylline in the treatment of early diabetic nephropathy. Tianjin medicine 4"},{"key":"2842_CR47","first-page":"3881","volume":"35","author":"F Zhao","year":"2019","unstructured":"Zhao F, Gao J, Yang D et al (2019) Effects of pentoxifylline on glucose metabolism and renal function in patients with early type 2 diabetic nephropathy. Modern J Integrat Tradition Chinese Western Med 35:3881\u20133883+3918","journal-title":"Modern J Integrat Tradition Chinese Western Med"},{"key":"2842_CR48","first-page":"905","volume":"11","author":"G Zhen","year":"2020","unstructured":"Zhen G, Ren G, Zhao Z (2020) Pharmacological mechanism and research advance of pentoxifylline on cardiovascular disease. World Clin Drugs 11:905\u2013909","journal-title":"World Clin Drugs"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02842-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02842-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02842-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:37:06Z","timestamp":1714991826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02842-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2842"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02842-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}